Kanika Monga, MD
Rheumatology · Houston, TXNPI 1982081915
Payments from drug & device makers
Across 234 payments — averaging $42.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$6K
- AbbVie$1K
- Johnson & Johnson$1K
- Amgen$361
- GSK$273
- AstraZeneca$153
- plus $832 from 18 others
What the payments were for
- Consulting fees$3,68037%
- Travel & lodging$1,69217%
- Food & beverage$4,32344%
- Education$1532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 21 | $5,691 |
| AbbVie | 76 | $1,341 |
| Johnson & Johnson | 53 | $1,197 |
| Amgen | 20 | $361 |
| GSK | 14 | $273 |
| AstraZeneca | 9 | $153 |
| Fresenius Kabi USA, LLC | 6 | $148 |
| Aurinia Pharma U.S., Inc. | 6 | $107 |
| Novartis | 5 | $101 |
| Boehringer Ingelheim | 4 | $81 |
| Pfizer | 3 | $67 |
| Novo Nordisk | 3 | $50 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $40 |
| Abbott | 2 | $33 |
| Grifols USA, LLC | 1 | $25 |
| Kedrion Biopharma, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
| Hospira, Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Biocryst US Sales Co., LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,848 in reported general payments places this provider in the 55th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KevzaraSarilumab | 11 | $47,007 |
| Hydroxychloroquine Sulfate | 88 | $3,010 |
| MethotrexateMethotrexate Sodium | 55 | $1,733 |
| Leflunomide | 23 | $1,319 |
| Mycophenolate Mofetil | 16 | $891 |
| Prednisone | 77 | $885 |
| Sulfasalazine DrSulfasalazine | 13 | $862 |
| Azathioprine | 13 | $604 |
| Celecoxib | 12 | $476 |
| Allopurinol | 23 | $198 |
| Folic Acid | 19 | $145 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Houston
- Philip WallerHouston$4.9M
- Qaiser RehmanHouston$2.3M
- Michelle EisenbergHouston$1.8M
- Abigail NeimanHouston$1.7M
- Maureen MayesHouston$1.6M
- Wajeeha YousafHouston$1.3M
- Laila HassanHouston$870K
- Shervin AssassiHouston$667K
- Jacqueline VoHouston$520K
- Naureen AlimHouston$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.